This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

IRIDEX Introduces Non-Invasive MicroPulse™ Therapy For Glaucoma

MOUNTAIN VIEW, Calif., April 27, 2012 /PRNewswire/ -- IRIDEX Corporation today announced the launch of a new non-invasive, in-office glaucoma procedure based on its proprietary MicroPulse™ technology.  The new glaucoma therapy, a tissue-sparing, repeatable therapy called MicroPulse Laser Trabeculoplasty (MLT), was introduced by IRIDEX at the recent American Society of Cataract and Refractive Surgery (ASCRS).

Glaucoma is the leading cause of adult irreversible blindness. It is estimated that more than 4 million people in the US and approximately 60 million people worldwide are afflicted with the disease today.

MLT was first introduced by IRIDEX in its infrared laser platforms, but recent technology advancements have now made it available with the IRIDEX green laser system (IQ 532), our most versatile and highest selling laser used by the broadest group of ophthalmologists. The unique ability of the IQ 532 to offer tissue-sparing repeatable therapies for both glaucoma and retinal diseases represents a market breakthrough as well as providing ophthalmologists a very high return on their capital investment, said Dr. Dominik Beck, IRIDEX President and CEO.

David Gossage, M.D., medical director of the Gossage Eye Institute, noted that the addition of the MicroPulse module to the IQ 532 system makes it a valid option for a much broader patient population than has historically been the case.

"Compared to other lasers used for the treatment of glaucoma, the IQ 532 with the MicroPulse module offers greater versatility because it can also be used for a range of other conditions including diabetic macular edema, proliferative diabetic retinopathy, and retinal tears," Dr. Gossage said.  "I'm comfortable offering MLT to glaucoma patients as a first-line option because of its potential to reduce intraocular pressure without causing tissue damage."

MLT produces laser pulses at very short durations to create a therapeutic response of lowering the intra-ocular pressure of a glaucoma patient without thermal damage. 

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,080.14 +21.45 0.12%
S&P 500 2,117.69 +4.76 0.23%
NASDAQ 5,092.0850 +36.0220 0.71%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs